Multi-centre, randomised, double-blind phase II study comparing cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma (DORIC Trial).
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Cediranib (Primary) ; Gefitinib
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms DORIC
- 03 Jul 2014 Planned End Date changed from 1 Nov 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
- 03 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 30 Oct 2012 Accrual to date is 33% according to United Kingdom Clinical Research Network.